Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Null Results in Brief

No Association between a Tetranucleotide Repeat Polymorphism of CYP19 and Prostate Cancer

Li Li, Mine S. Cicek, Graham Casey and John S. Witte
Li Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mine S. Cicek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Casey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John S. Witte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published December 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
  • case-control study
  • CYP19
  • (TTTA)n repeats
  • polymorphism
  • prostate cancer

Introduction

The CYP19 gene encodes the enzyme aromatase, which plays a key role in the conversion of androgen to estrogen. The prostate is influenced by estrogen from peripheral sources as well as through aromatase activity in its stroma (1). There is evidence of elevated levels of aromatase activity and mRNA expression in stromal cells in prostate cancer as well as increasing evidence of cross-talk between estrogens and androgens in regulating gene expression in the prostate (2, 3). Moreover, estrogens compete with androgens for fastening to sex hormone binding protein, and it is believed that sex hormone binding protein synthesis is modulated by, and is a reflection of, estrogen/androgen balance (4). Thus, it is possible that genetic variations in CYP19 will alter the availability of sex steroid hormones and an individual's risk of prostate cancer.

A tetranucleotide (TTTA)n repeat polymorphism in intron 4 of the CYP19 gene is hypothesized to alter aromatase activity, and the (TTTA)7 and (TTTA)11 alleles have been associated with risk of prostate cancer in one previous study (5). The role of the CYP19 (TTTA)n repeat polymorphism in the etiology of prostate cancer thus remains unclear. We present here the results from a sibling-matched, case-control study to further clarify the potential relation of this genetic polymorphism with prostate cancer.

Materials and Methods

The design of our study has been described in detail elsewhere (6). Briefly, we recruited a study population of 918 brothers (439 cases and 479 controls) from 413 discordant families (i.e., with at least one unaffected sibling) from the major medical institutions in the greater Cleveland, OH area and from the Henry Ford Health System in Detroit, MI. Institutional review board approval was obtained from the participating institutions and all study participants gave informed consent. Sibling sets consisted of probands with prostate cancer diagnosed at age ≤73 years and at least one brother without prostate cancer who was either older or no more than 8 years younger than the proband's age at diagnosis. The study population was composed of 91% Caucasian, 8% African American, and 1% Hispanic and Asian American. Genotyping was undertaken according to assays described recently elsewhere (5).

We first calculated allele frequencies by disease status and then estimated age-adjusted odds ratios and 95% confidence intervals by conditional logistic regression (matched on family) for the association between the polymorphisms and prostate cancer. The CYP19 (TTTA)n repeat was modeled at the genotype and allele levels. In reference to the report by Latil et al. (5), we first used the homozygous (TTTA)7/(TTTA)7 as our reference for the genotype-level analysis and created the following five genotype categories for comparison: (1) (TTTA)<7/(TTTA)<7, (2) (TTTA)<7/(TTTA)7, (3) (TTTA)<7/CA≥8, (4) (TTTA)7/(TTTA)≥8, and (5) (TTTA)≥8/(TTTA)≥8. We further collapsed these five comparison categories by combining those heterozygous for the (TTTA)7 repeat (groups 2 and 4 above) and those without any (TTTA)7 repeats (groups 1, 3, and 5). We also used the homozygous (TTTA)11/(TTTA)11 as the reference and carried out similar analysis. At the allele level, we modeled chromosomes as a continuous variable and with the following categorizations: (1) (TTTA)7 (reference), (2) (TTTA)<7, and (3) (TTTA)>7 or (1) (TTTA)11 (reference), (2) (TTTA)<11, and (3) (TTTA)>11.

To investigate the potential effect of these polymorphisms on prostate cancer aggressiveness, we undertook analyses stratified by the cases tumor stage and grade at diagnosis; men with tumor stage of ≥T2c or Gleason score ≥7 (and their control brothers) were categorized as having high stage/grade; others were considered low stage/grade. In our regression models, we investigated the potential confounding by age, height, and body mass index; the latter two did not materially alter our results, and all results reported here are adjusted for age only.

Results and Discussion

Genotypes of two cases did not amplify, leaving 436 cases available for our analyses. No noteworthy difference was observed in the frequency of CYP19 (TTTA)n repeat polymorphism between cases and controls (Table 1). Logistic regression analyses revealed no association with prostate cancer (Table 2). Specifically, we observed no association between CYP19 (TTTA)n repeat polymorphism and prostate cancer regardless of how this was modeled (for brevity sake, we only report results from genotype-level analysis). Stratifying these analyses by the stage/grade of prostate cancer or age at diagnosis of the cases did not materially alter our null results (data not shown). Furthermore, restricting the analyses to Caucasians only did not affect our findings.

View this table:
  • View inline
  • View popup
Table 1.

Allele frequency of CYP19 (TTTA)nrepeat polymorphism by prostate cancer status

View this table:
  • View inline
  • View popup
Table 2.

Relationship between CYP19 (TTTA)nrepeat polymorphism and prostate cancer risk

By using a sibling-based design, our results are not susceptible to population stratification bias. However, this design can be less efficient than a study of unrelated cases and controls. Nevertheless, our study had >80% power to detect an odds ratio ≥ 1.75 for the polymorphisms studied here. In conclusion, this moderately large case-control study did not detect an association between CYP19 (TTTA)n repeat polymorphism and risk or aggressiveness of prostate cancer.

Footnotes

  • Grant support: NIH grants CA88164 and CA94211, Department of Defense grant DAMD 17-98-1-8589, and Damon Runyon Cancer Research Foundation grant CI-8 (L. Li).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted June 18, 2004.
    • Received May 31, 2004.

References

  1. ↵
    Vogt K, Bartsch W. Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J Steroid Biochem Mol Biol 1986;25:749–57.
    OpenUrl
  2. ↵
    Hiramatsu M, Maehara I, Ozaki M, Harada N, Orikasa S, Sasano H. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 1997;31:118–24.
    OpenUrlCrossRefPubMed
  3. ↵
    Yeh S, Miyamoto H, Shrima H, Chang C. From estrogen to androgen receptor: a new pathway for sex hormone in prostate. Proc Natl Acad Sci U S A 1998;95:5527–32.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Farnsworth WE. Roles of estrogen and SHBE in prostate physiology. Prostate 1996;28:17–23.
    OpenUrlCrossRefPubMed
  5. ↵
    Latil AG, Azzouzi R, Cancel GS, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92:1130–7.
    OpenUrlCrossRefPubMed
  6. ↵
    Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes, haplotypes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:928–32.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 13 (12)
December 2004
Volume 13, Issue 12
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
No Association between a Tetranucleotide Repeat Polymorphism of CYP19 and Prostate Cancer
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
No Association between a Tetranucleotide Repeat Polymorphism of CYP19 and Prostate Cancer
Li Li, Mine S. Cicek, Graham Casey and John S. Witte
Cancer Epidemiol Biomarkers Prev December 1 2004 (13) (12) 2280-2281;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
No Association between a Tetranucleotide Repeat Polymorphism of CYP19 and Prostate Cancer
Li Li, Mine S. Cicek, Graham Casey and John S. Witte
Cancer Epidemiol Biomarkers Prev December 1 2004 (13) (12) 2280-2281;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Soft drink and juice consumption and renal cell carcinoma
  • Associations of ACEi and ARB with CRC Risk
  • Telomere length and TGCT risk
Show more Null Results in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement